Industry
The UK Parkinson’s Disease Clinical Studies Group (UK PD-CSG) unites Parkinson’s researchers across the whole of the UK. The Group is composed of research interested clinicians and clinician scientists from diverse disciplines with patient and public involvement representative members. The UK PD-CSG works together to promote research to develop better treatments and care for people affected by Parkinson’s. We are keen to work with industry to support early feasibility assessments, and quickly identify sites with capacity to deliver their trial.
Support Offered:
Early Feasibility Assessment
Logistical Advice
The group can give up to date, accurate advice on whether a study would be feasible for the research delivery staff within the NHS and clinical community. The group has extensive experience working with NHS Trusts across the UK.
Site Selection Process
Information Sharing
Comprehensive knowledge of infrastructure, capacity and eligibility of existing sites
Geographical Distribution
Information about potential future study sites to aid more even geographical distribution of clinical trials across the UK
Trained Research Sites
Quality of Research
Support training of researchers
Promote more standardised clinical trial activities across UK sites
Efficiency
More efficient communication
Facilitate faster setup processes with fewer delays
Cost Saving
More rapid delivery of clinical trials through increased workforce qualified to undertake Parkinson's clinical trials across the UK
New Sites & Researchers
Support for New Sites
Support for sites less experienced in clinical research through UK PD-CSG Buddy Scheme with more experienced sites and other measures
Support for Parkinson's Professionals New to Research
Opportunity for one to one advice sessions with more experienced UK PD-CSG members
Provide training opportunities
Interested in collaborating?
Contact Emma Fargher
Guidance for Costing Clinical Trials
UK PD-CSG NCVR Guidance Document v1 26.01.2024.pdfThis document has been developed by the UK PD-CSG and the NCVR PD Document Development Working Group to assist the life sciences industry and lead study sites with costing commercially sponsored Parkinson’s Disease (PD) clinical trials within the NHS.
It is intended to be used as a guidance document to assist with completion of the NIHR interactive Costing Tool (iCT) and should be read alongside the associated NIHR costing guidance, NIHR iCT Tariff Costs and relevant study documents. It will support the UK lead site (where the CI is based) and Industry sponsors to consider all costs and accurately capture the true resources required during the national contract value review (NCVR), to reduce protracted negotiations being required at each site when the budget is shared with other participating sites.
The NIHR iCT provides a framework to enable transparency and consistency of costs and to support NHS sites in budget negotiations with commercial sponsors. The NIHR iCT tariff costs are simply a guide and provide suggested timings to aid the completion of the iCT. These suggested timings and costs within the iCT tariff are generic and cannot consider the variability in different therapy areas. PD clinical studies are often complex and due to patients’ varying levels of disability, the time taken to complete even straight-forward procedures can take considerably longer than in healthy participants. This guidance document is intended to support costings by providing procedure times that are specific to PD. Trials involving atypical Parkinsonism should consider the likely variability in some activity length, such as examination visits, due to the complexity of the patient population.
Collaborations with Industry
The UK PD-CSG endeavours to develop successful relations with leading Industry and Commercial Partners in Parkinson's clinical research.
Group membership represents research sites across the whole of the UK. By working directly with investigators, we can provide accurate and up-to-date information, and implement strategies to increase capacity or develop capabilities to support Parkinson’s studies. We encourage commercial sponsors to engage with the Group at the earliest stages of development, to ensure we can feed into study designs and ensure they will be deliverable in the UK.